Table 2. Detection of viral DNA in treated and control animals.
| Animals positive by TaqMan PCR | |||||
| Group | Stage 20 | Stage 28 | Stage 33 | Stage 42 | Post TR |
| A: uninfected s/nate | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 |
| B: rBIVneor 102 dose | 0/5 | 1/5 | 0/5 | 0/5 | 0/3 |
| C: rBIVneor 103 dose | 0/5 | 2/5 | 0/5 | 0/5 | 0/3 |
| D: rBIVneor 104 dose | 0/5 | 5/5 | ND | ND | ND |
| E: rBIV/neor/adglob 102 dose | 0/5 | 0/5 | 1/5 | 1/5 | 0/5 |
| F: rBIV/neor/adglob 103 dose | 0/5 | 2/5 | 2/5 | 4/5 | 0/3 |
| G: rBIV/neor/adglob 104 dose | 0/5 | 4/5 | ND | ND | ND |
Number of animals out of 5 sampled from each group that returned a positive result in TaqMan real time PCR for the presence of viral DNA. ND: not taken as tadpole numbers were reduced at the highest virus dose and preference was to maximise the number of animals for analysis of globin at 1–2 weeks post tail resorption (TR). Ct values of >35, corresponding to <10 copies of the BIV genome were considered indeterminate and recorded as a negative result.